~~<i id='A48394F3B0'><strike id='A48394F3B0'><tt id='A48394F3B0'><pre id='A48394F3B0'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：fashion 2025-08-10 09:23:36 Page View：582

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： PBMs drew scrutiny in House hearing — and so did pharma
Next article： Guidelines to prevent youth baseball injuries need more muscle

leisure time

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Neurocrine congenital adrenal hyperplasia trial succeeds

AdobeSANDIEGO—NeurocrineBiosciencesannouncedonTuesdaythatanexperimentaldrugforcongenitaladrenalhyper

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

FDA gives detailed accounting of AI

AdobeTheFoodandDrugAdministrationonThursdayreleasedanewaccountingofartificialintelligencetoolscleare